FDA strongly encourages companies to continue to develop new, reliable ways to minimize animal testing and to provide the data necessary for the FDA to make a GRASE determination for sunscreen active ingredients.
Similar Posts
Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 20 mEq Potassium Chloride Injection Due To Overwrap Mislabeled As 10 mEq Potassium Chloride Injection
FOR IMMEDIATE RELEASE – October 31, 2025 AUSTIN, TX – Otsuka ICU Medical LLC is issuing a voluntary recall to the user level, for a MISLABELLED lot of POTASSIUM CHLORIDE Inj. 20 mEq, NDC 0990-7077-14. The OVERWRAP label of lot 1030613, Expiration Date: 09-30-2026 may incorrectly identify the productmotionpharmacy.com – 715595 – 09/10/2025
Unapproved New Drug/MisbrandedLupin Limited – 09/16/2025
Lupin Limited – 09/16/2025. Country: India. Record Type: 483ICH M13B Webinar: Navigating the Draft ICH M13B Additional Strengths Biowaiver Guideline – 09/11/2025
This webinar will provide an in-depth look at the draft ICH M13B guideline titled “Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver” that was endorsed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Assembly in March 2025.Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement – FDA Safety Communication
Read the FDA’s recommendations related to Accolade pacemaker devices by Boston Scientific and a potential need for early device replacement.ByHeart Inc. dba BlendHouse Allerton. Allerton, IA. EIR issued 01/30/2024
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 01/30/2024
Short Title (70 char) ByHeart Inc. dba BlendHouse Allerton. Allerton, IA. EIR issued 01/30/2024
FEI Number 1921383
Firm Name ByHeart Inc. dba BlendHouse Allerton
Record Type EIR
State IA
Establishment